Background: Methotrexate, an anti-proliferative, anti-inflammatory, and immunomodulating medication, was licensed by the United States Food and Drug Administration (FDA) in 1971. Methotrexate is still used as standard systemic therapy for moderate to severe psoriasis that has not responded to topical therapy due to its low cost, great efficacy, and quick outcomes. Once the cumulative dose (1.0-1.5 gm.) is reached, a fast and dramatic reaction may be observed. We aimed to present an Insight about Role of Methotrexate in Treatment of psoriasis.

Conclusion: While methotrexate was initially used to treat cancer, it has now shown promise in treating a variety of non-neoplastic proliferative skin conditions, such as psoriasis. A unique perspective on the findings and new information regarding MTX over time is provided by the guidelines for its usage in psoriasis patients. Traditional systemic treatment for moderate to severe psoriasis has mostly relied on it for a long time. As a matter of fact, the drug has been licensed by the USDA for the treatment of psoriasis since 1972, and the most current recommendations state that it is still the main treatment for moderate to severe psoriasis